期刊
PHARMACEUTICALS
卷 15, 期 1, 页码 -出版社
MDPI
DOI: 10.3390/ph15010049
关键词
neurosteroids; anticonvulsant; zuranolone; NMDA; GABA; metabolomics
Pregnanolone glutamate (PA-G) is a neuroactive steroid that exhibits potent neuroprotective effects. It inhibits N-methyl-D-aspartate receptors and potentiates gamma-aminobutyric acid receptors (GABA(A)Rs). PA-G has demonstrated strong anticonvulsant effects in different age groups, and its mechanism of action appears to be different from zuranolone, another neurosteroid.
Pregnanolone glutamate (PA-G) is a neuroactive steroid that has been previously demonstrated to be a potent neuroprotective compound in several biological models in vivo. Our in vitro experiments identified PA-G as an inhibitor of N-methyl-D-aspartate receptors and a potentiator of gamma-aminobutyric acid receptors (GABA(A)Rs). In this study, we addressed the hypothesis that combined GABA(A)R potentiation and NMDAR antagonism could afford a potent anticonvulsant effect. Our results demonstrated the strong age-related anticonvulsive effect of PA-G in a model of pentylenetetrazol-induced seizures. PA-G significantly decreased seizure severity in 12-day-old animals, but only after the highest dose in 25-day-old animals. Interestingly, the anticonvulsant effect of PA-G differed both qualitatively and quantitatively from that of zuranolone, an investigational neurosteroid acting as a potent positive allosteric modulator of GABA(A)Rs. Next, we identified 17-hydroxy-pregnanolone (17-OH-PA) as a major metabolite of PA-G in 12-day-old animals. Finally, the administration of PA-G demonstrated direct modulation of unexpected neurosteroid levels, namely pregnenolone and dehydroepiandrosterone sulfate. These results suggest that compound PA-G might be a pro-drug of 17-OH-PA, a neurosteroid with a promising neuroprotective effect with an unknown mechanism of action that may represent an attractive target for studying perinatal neural diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据